Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).
Gastric or Gastroesophageal Junction Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Biliary Tract Cancer (BTC)
DRUG: Spevatamig (PT886)|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Abraxane|DRUG: KEYTRUDAÂ® (pembrolizumab)|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: Fluorouracil|DRUG: Capecitabine|DRUG: FOLFIRINOX
To determine the dose-limiting toxicity (DLT) of Spevatamig (PT886)., Through study completion.|To determine the maximum tolerated dose (MTD) of Spevatamig (PT886)., Through study completion.|To evaluate the safety and tolerability of Spevatamig (PT886)., Through study completion, an average of 2 years
To evaluate the pharmacokinetics of Spevatamig (PT886)., Through study completion, an average of 2 years|To evaluate the immunogenicity (ADA) of Spevatamig (PT886)., Through study completion, an average of 2 years|Preliminary Efficacy of Spevatamig (PT886)., Through study completion.
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).